Puberty Blockers

Sarah Owen Excerpts

Tuesday 23rd June 2026 Commons Chamber

[Sarah Owen (Luton North) (Lab)]

It is a pleasure to follow the hon. Member for Mid Sussex (Alison Bennett). I wholeheartedly agree with her points about the importance of talking therapies. Those are incredibly important tools for children who are in gender distress. We need to see greater access to talking therapies for all children in a timely fashion.

May I first say that there is far too much debate about trans people without them? We would not tolerate this in any other debate. Yet somehow, whether in the media or in politics, in debate after debate—online, in the media and in this place—we talk about trans people and people in gender distress without acknowledging that we are lucky to be born into a body we identify with. I will never know the pain of gender distress. There are times when I look in the mirror and I think, “God, I wish I could change this.” Usually, I wish I could not look so tired, but I do not know what it is like to not be in a body that I identify with; I am fortunate and therefore speak from a position of great privilege.

I will start with the words of one of my constituents, an 83-year-old trans woman called Teraina. She said, “I was born a male but I have never been a man. I tried but I failed. I always have felt female. Even at school as a boy, I was bullied for being”—in her words—“a ‘sissy’ so I left. I am 83. I have lived my life. This is about the future generations and the others who come next.”

Teraina discharged herself from hospital to have that conversation with me because she feels so strongly about future generations: that they should not be bullied for who they are; that they should be able to access treatment; and that they should be able to be who they are. We must get this right for the future generations of people like Teraina, because too many have lost their lives, or have suffered, living a life that was not fully theirs.

It is fair to say that there is a varied range of views in the Cass review. However, if future access to treatment for gender dysphoria is dependent on more research, it is vital that the Pathways trial goes ahead with the additional safeguards now put in place. Whatever one’s views on the trial, it is clear that every step has been taken to put the safety of patients at its heart. It has been designed by experienced clinical researchers and checked by independent scientists who advise the National Institute for Health and Care Research, and has included independent academic peer reviewers. As with all clinical trials, this one will be overseen by the data monitoring committee, as the safety and wellbeing of those taking part is vital.

All those safeguards should be welcome. After all, those people are the experts when it comes to the medical procedures and the science. The experts when it comes to individual children, however, are the parents. Both today and yesterday, some of the rhetoric around the statement has ignored the important role of parents in the trial.

[James Asser (West Ham and Beckton) (Lab)]

I know the constituent my hon. Friend has spoken about. My hon. Friend also makes a valuable point about the need to speak with people who have lived a life, given that these things have been done in ignorance. Her point about parents is key. I have a constituent who is trans whose parents have engaged with me and explained the difficulties of learning to deal with and manage the situation. Their voices, alongside those of clinicians, are really important in understanding the issues. Does my hon. Friend agree?

[Sarah Owen]

Absolutely. I thank my hon. Friend for his commitment to the LGBT+ community and for his work, including with his constituents. We have heard a lot today about throwing children into wild experiments, but that is not what we are talking about. We are talking about something done in collaboration with parents—parents who love their children and want the best for them, and with medical professionals who want the same. The rhetoric around the trial really needs to change.

No child will be able to take part in the trial without parental consent. That has been confirmed again by the Secretary of State from the Dispatch Box. Of course, there will be some children who will never gain their parents’ consent: a heartbreaking situation for any family. However, there will be many parents who will truly support and know the wishes of their child; they will agree with the suitability of the treatment and want to support them on their journey.

Much has been discussed about the child, but parents have huge agency in the process. We are not just talking to the children; we are talking to adults who want the best for their child, and that point should be recognised.

[Iqbal Mohamed]

My hon. Friend is making a powerful speech. I have huge respect for her and I completely agree that nobody here or outside should be looking to disrespect or harm any individual, whatever their age. Would she agree that parents should also be given all the information available around this condition, its treatments and the paths that children follow? Over 93% of children who experience gender dysphoria grow out of it and then are happy in their natural body. Does she agree that that and other information should be made available to the parents?

[Sarah Owen]

I thank the hon. Member for his intervention and his kind words at the beginning; that is the right tone, which we need to set, and information is key. People need to be able to make informed decisions—whether it is the child or a parent—and there needs to be independent information so that people can make fully informed decisions.

[Danny Beales (Uxbridge and South Ruislip) (Lab)]

My hon. Friend is making a powerful and moving speech. Further to her point, does she not agree that the Opposition’s motion to prevent a clinical trial would not give people information, options and choices? It would cut down information, options and choices. She mentioned a constituent in her 80s who clearly did not grow out of her gender dysphoria, and this motion would close off lifesaving and life-changing treatment for the 7% of people who do not grow out of gender dysphoria.

[Sarah Owen]

I thank my hon. Friend for his powerful intervention; absolutely, information and scientific evidence are key, and this trial will be conducted by experts with patients’ best interests at heart. We have heard from the Opposition spokesperson, the hon. Member for Sleaford and North Hykeham (Dr Johnson), and I am sure that, as a doctor, she cares about her patients as much as all the doctors and clinical specialists that will be involved in these trials.

Last year, the Women and Equalities Committee held a one-off inquiry into the safety and effectiveness of puberty blockers. We stuck to the science. There were different views on our panel of witnesses, but I wanted to demonstrate something that has, sadly, not happened very often around this topic, which was that we could discuss it in a sensitive, respectful way, based on fact, not opinion—not for social media clips or for likes on a particular outlet’s sidebar of shame, but for the good of the people we represent.

We also examined the use of puberty blockers for other medical purposes—something that has not been discussed today when talking about the risks, or perceived risks, of puberty blockers. It is commonplace to use puberty blockers for certain cancers, for endometriosis and for children experiencing premature sexual maturity, also known as precocious puberty. When it comes to cancers such as prostate cancer, the professors on the panel described the need to essentially “turn off” testosterone. This is now a commonplace treatment for prostate cancer.

Another use of puberty blockers is for endometriosis. We already know the disgraceful delays in diagnosis and treatment for endometriosis and adenomyosis, with women waiting at least 10 to 13 years just for a diagnosis. They are living in pain for far too long, but experts are using puberty blockers, again, to essentially “turn off” menstruation and oestrogen for women with severe endometriosis.

[Esther McVey (Tatton) (Con)]

I thank the hon. Lady for giving way; I am listening to her very intently. Does she know what a measure of success would be in this puberty blocker trial? If 80% of the children on it were happy with the outcome, would that be a success? What are the ultimate measurements of success?

[Madam Deputy Speaker (Ms Nusrat Ghani)]

Order. The hon. Member for Luton North (Sarah Owen) is making an important speech, but before she gets back to her feet, I must tell her that I need to get 12 more Members in to speak.

[Sarah Owen]

I know that further details will be coming from the Secretary of State as to what a marker of success is, but I think we have to ask ourselves what a marker of success is for the individuals and families. For some, staying in their sex from birth may look like success. For others, that will not be the case. This is very much on the individual.

[Dr Arthur]

Will my hon. Friend give way on that point?

[Sarah Owen]

I will not; I am going to make some progress, as I have been duly told to do.

The treatment of premature sexual maturity, or precocious puberty, in children—this is for children—uses puberty blockers now. The professors reported to our Committee that puberty blockers are

“recognised as a reversible treatment.”

Professor Butler added that we know

“from follow-up studies with children who have received it for precocious puberty that there are no ill health effects in the long term nor are there any negative effects on fertility recovery.”

Professor Grossman pointed to a “huge amount of evidence” from Harvard University highlighting successful treatment and outcomes for girls prescribed puberty blockers for premature sexual maturity

“in terms of fertility and their subsequent life.”

[Joy Morrissey]

Will the hon. Lady give way?

[Sarah Owen]

I am not going to take any more interventions, as I have been told that I need to crack on.

These puberty blockers are the same drugs, prescribed in the same way, but instead of treating gender distress, they are treating prostate cancer, endometriosis and premature sexual maturity in children. Yet we have heard no call from scientists, campaigners or the medical community to stop the use of puberty blockers for those treatments.

Some have been critical of the trial going ahead, but what happens to young people experiencing gender distress if it does not? Dr Hilary Cass believes that without a trial, young people will continue to get drugs from “unregulated and dangerous routes”, and my Select Committee heard evidence to support that. Unfortunately, young people are now self-treating because they see no other option. They are getting hold of medication from abroad, with no assessment, support or medical advice. Dr Hilary Cass was right to say that she is

“absolutely convinced that more children will be harmed if we don’t do the trial than if we do.”

For me, safety is paramount, but this is an issue of access to healthcare, and there should never be a block to healthcare for anyone. While the trial goes forward, many young people, younger and older, will be scared and frightened about what the future holds. I hope that the Secretary of State can address the hostile environment for young trans people, as well as what support outside of legislation and the medical world needs to be more widely available for people in gender distress and the entire LGBTQ+ community.